LDH-A Inhibitor as a Remedy to Potentiate the Anticancer Effect of Docetaxel in Prostate Cancer

Basit Öğe Kaydı
dc.authoridEren Gozel, Hilal/0000-0001-6026-6052;
dc.authorwosidEren Gozel, Hilal/AAJ-6433-2021
dc.authorwosidAyla, Sule/JNS-6355-2023
dc.contributor.authorCakici, Cagri
dc.contributor.authorDaylan, Benay
dc.contributor.authorUnluer, Ruveyde Safiye
dc.contributor.authorEmekli-Alturfan, Ebru
dc.contributor.authorAyla, Sule
dc.contributor.authorGozel, Hilal Eren
dc.contributor.authorYigit, Pakize
dc.date.accessioned2024-05-19T14:46:19Z
dc.date.available2024-05-19T14:46:19Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractIncreased LDH-A activity promotes tumor growth, migration, invasion, and metastasis. This study aimed to investigate the effects of the combination of LDH-A inhibitor and Docetaxel on apoptosis and epithelial-mesenchymal transition (EMT) in the murine prostate cancer (PCa) model. The prostate cancer murine model was developed subcutaneously in 50 male B57CL/6 mice using the Tramp -C2 prostate cancer cell line. From the tumor tissue samples, apoptosis analysis was performed using TUNEL staining, and EMT was investigated using western blot and qPCR. Hematoxylin-eosin staining (HE) and Periodic acid-Schiff staining were used to histopathologically examine liver and kidney tissues. Lactate levels revealed that the Warburg effect was reversed with the LDH-A inhibitor. Both serum and tumor tissue apoptosis increased, and tumor sizes reduced in PCa+LDH-A inhibitor + Docetaxel treatment groups (p<0.05). The combination of LDH-A inhibitor and Docetaxel inhibited EMT mechanism by causing a decrease in Snail, Slug, Twist, and HIF-1 alpha expressions as well as a decrease in N-cadherin and an increase in E-cadherin levels. Reprogramming glucose metabolism with an LDH-A inhibitor can increase the effectiveness of Docetaxel on apoptosis and metastasis mechanisms in PCa.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey [119S850]; Istanbul Medipol University Scientific Research Projects Unit; [2018/16]en_US
dc.description.sponsorshipThis work was supported by grants from The Scientific and Technological Research Council of Turkey (Grant no: 119S850) , and Istanbul Medipol University Scientific Research Projects Unit (Grant no:2018/16) .en_US
dc.identifier.doi10.7150/jca.86283
dc.identifier.endpage602en_US
dc.identifier.issn1837-9664
dc.identifier.issue3en_US
dc.identifier.pmid38213726en_US
dc.identifier.scopus2-s2.0-85185716416en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage590en_US
dc.identifier.urihttps://doi.org10.7150/jca.86283
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5496
dc.identifier.volume15en_US
dc.identifier.wosWOS:001167297900004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherIvyspring Int Publen_US
dc.relation.ispartofJournal of Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectProstate Canceren_US
dc.subjectApoptosisen_US
dc.subjectEmten_US
dc.subjectLdh-A Inhibitoren_US
dc.subjectWarburg Effecten_US
dc.titleLDH-A Inhibitor as a Remedy to Potentiate the Anticancer Effect of Docetaxel in Prostate Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu